Rigor Reviewed

Rigor-Reviewed Manuscript

Effects of tirzepatide on circulatory overload and end-organ damage in heart failure with preserved ejection fraction and obesity: a secondary analysis of the SUMMIT trial.

Name: Αlpha¹ Rigor Record — Effects of tirzepatide on circulatory overload and end-organ damage in heart failure with preserved ejection fraction and obesity: a secondary analysis of the SUMMIT trial.
Item: Effects of tirzepatide on circulatory overload and end-organ damage in heart failure with preserved ejection fraction and obesity: a secondary analysis of the SUMMIT trial.
Rating: 39
Author: Αlpha¹

Borlaug BA, Zile MR, Kramer CM, Baum SJ, Hurt K, Litwin SE, Murakami M, Ou Y, Upadhyay N, Packer M

Paper source

Read full text (PMC)

Embed this Rigor badge

$Αlpha¹ Rigor Review — 1★ (Critical), 4 critical, 0 high issues for “Effects of tirzepatide on circulatory overload and end-organ damage in heart failure with preserved ejection fraction and obesity: a secondary analysis of the SUMMIT trial.”$

Links back to this Rigor Record.

Αlpha¹ Editorial

This rigor review was examined and confirmed by Αlpha¹ Editorial · August 16, 2026

Αlpha¹ Rigor Review

Rigor Reviewed

1 / 5

Critical — a demonstrable failure

Interventional Study

Critical

High-priority

How this rating was calculated▸

Started at 5★ — deductions

StatisticsImpossible or misreported statistic ×4−4★
IntegrityIntegrity concern ×3−1.5★
ClaimsEfficacy rests on an unvalidated surrogate endpoint−0.5★
ClaimsTreatment effect not shown to be clinically meaningful−0.5★
StatisticsPrinted percentage does not match its own count (capped) ×4−0.25★

A demonstrable critical failure caps the rating at the minimum, regardless of the deductions above.

Model-reported confidence: highReviewer agreement: highEngine: 7.39.0Source: full text

Not verified in this report

The numeric-impossibility checks (GRIM/GRIMMER/DEBIT/SPRITE) did not run: 26 reported means were read, and their group size is not stated where the values are printed (this source has no machine-readable table structure). These checks need the count the mean was averaged over, so none was performed.

Problems surfaced7 types

Numerical inconsistencies3

Values that contradict each other or are impossible for the stated sample: recomputed p-values and test statistics, GRIM/GRIMMER checks on summary numbers, percentages against their own counts, totals against their parts, and estimates against their own confidence intervals.

Summary statistic impossible for the stated N (GRIM/GRIMMER)Recomputed
Printed percentage does not match its own countRecomputed
Internal contradictions in the reported numbersAssessed

Overstated conclusions3

Conclusions that reach past what the paper's own results support — including a significance claim that no longer holds when the statistic is recomputed, and efficacy resting on an unvalidated surrogate endpoint.

Efficacy rests on an unvalidated surrogate endpointAssessed
Treatment effect not shown to be clinically meaningfulAssessed
Conclusions only partially backed by the presented evidenceAssessed

Data authenticity concerns1

An adversarial read for patterns associated with data that may not be genuine: results that look too clean, implausibly large effects, duplicated data or images, and methods that do not match the results reported.

Other integrity concernAssessed

This Αlpha¹ Rigor Review uses AI Rigor Reviewers trained on a curated corpus of high-fidelity and retracted papers, with expert supervision and curation. It can still make mistakes; verify each finding against the source before relying on it.

Critical findings

• PERCENT: 42.2% does not match the reported count 151/364
• PERCENT: 40.6% does not match the reported count 147/367
• PERCENT: 66.6% does not match the reported count 233/364
• PERCENT: 65.6% does not match the reported count 227/367

This is a well-conducted secondary analysis of a randomized controlled trial, with rigorous design, clear reporting, and appropriate statistical methods. Minor reporting gaps include lack of explicit randomization method details, no power analysis for secondary outcomes, and unidentified statistical software. The paper is methodologically sound and transparent.

Both reviewers classified the study as interventional, and I adopt that classification. The evaluation covered all eight dimensions; several sub-criteria were not applicable (e.g., animal-related items, code sharing). The statistics verification component could only recompute a subset of tests; the rest remain unverified but no errors were found.

11 major claims checked against the paper's own evidence: 1 only partially supported (evidence backs part of the claim; gaps or caveats remain); the rest adequately supported.

Premise concern: surrogate not validated for clinical benefit; effect size not shown to be clinically meaningful.

Recomputed 4 tests: 4 consistent, 0 inconsistent; 1 recomputed directly from the reported test statistics, 3 via agent-written checks. 4 reported summary statistics mathematically impossible for the stated N (PERCENT). 4 printed percentages that do not match their own count.

3 integrity concerns flagged (0 high).

Reporting

Eight Dimensions8 pass

The introduction cites multiple prior studies establishing the pathophysiologic features of obesity-related HFpEF, including volume expansion, inflammation, and end-organ damage, and references the SUMMIT trial's primary results. The rationale for the mechanistic analysis is clearly stated: to test whether tirzepatide reduces circulatory volume-pressure overload and systemic inflammation, thereby mitigating end-organ injury. Limitations of prior work are implicitly addressed by the design of the SUMMIT trial and the prespecified nature of most outcomes, though the paper does not explicitly discuss limitations of prior mechanistic studies.

Sub-criteria

prior work citedADEQUATE

premise rationaleADEQUATE

limitations addressedINADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

The paper establishes a clear scientific premise by citing prior work on obesity-related HFpEF, volume overload, inflammation, and the SUMMIT trial, and links this to the hypothesis that tirzepatide reduces circulatory overload and end-organ damage.

Evidence

paraphrase[Introduction, paragraphs 1-3]

“Obesity-related HFpEF represents the most advanced form of cardiovascular–kidney–metabolic disease, a syndrome recognized by the American Heart Association.”

direct quote[Introduction, last paragraph]

“Here, we tested the hypothesis that tirzepatide may reduce cardiovascular–kidney end-organ damage while exerting favorable effects on circulatory volume–pressure overload and systemic inflammation in patients with obesity-related HFpEF participating in the SUMMIT trial.”